Shenzhen Hepalink Pharmaceutical Group (09989) reported a net profit attributable to shareholders of RMB394 million for the first three quarters, down 28.84% year on year.
Shenzhen Hepalink Pharmaceutical Group (09989) announced its results for the first three quarters of 2026. The group recorded operating revenue of RMB3.797 billion, down 9.48% year on year; net profit attributable to shareholders of the listed company was RMB394 million, down 28.84% year on year; basic earnings per share were RMB0.2685.
Shenzhen Hepalink Pharmaceutical Group (09989) announced its results for the first three quarters of 2026. The Group recorded operating revenue of RMB3.797 billion, down 9.48% year on year; net profit attributable to shareholders of the listed company was RMB394 million, down 28.84% year on year; basic earnings per share were RMB0.2685.
Related Articles
SHOUCHENG (00697) repurchased 5.55 million shares on October 29 for HK$6.659 million.
ZERO2IPO (01945) repurchased 2,000 shares on October 29 for HK$2,598.
DAWNRAYS PHARMA (02348) repurchased 44,000 shares for HK$40,500 on October 29.
SHOUCHENG (00697) repurchased 5.55 million shares on October 29 for HK$6.659 million.
ZERO2IPO (01945) repurchased 2,000 shares on October 29 for HK$2,598.
DAWNRAYS PHARMA (02348) repurchased 44,000 shares for HK$40,500 on October 29.
